FDA grants tentative approval of UCERIS for ulcerative colitis

The FDA has granted tentative approval for UCERIS, a rectal foam for remission induction in mild to moderate distal ulcerative colitis.

UCERIS, developed by Salix Pharmaceuticals, is a rectally administered corticosteroid. The tentative FDA approval means the product meets quality, safety and efficacy standards, but awaits resolution of patient issues before receiving final approval.

More articles on gastroenterology:
19 things to know about GI compensation & satisfaction in 2014
How has the Obama presidency affected the field of GI?
Will CMS cover virtual colonoscopy?

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast